HIV Clinical Trial
Official title:
Evaluation of the Safety and Acceptability of the PrePex™ Device for Male Circumcision in Zambia
The study will measure the incidence of moderate and severe adverse events (AEs) associated with PrePex procedures among 500 men, including both procedural and post-procedure events, and all device-related incidents such as dislodgment. To assure complete ascertainment of AEs, study-specific forms will be used to collect standardized data from the circumcision visit and all follow-up visits. Follow-up will be more intensive for the first 50 cases, and will transition to follow-up at two visits (7 and 42 days) for the remaining 450 cases.
The World Health Organization, the Joint United Nations Programme on HIV/AIDS (UNAIDS), and
other global reproductive health organizations have recognized the protective effect of male
circumcision in HIV acquisition. Male Circumcision(MC) is one of the few biomedical methods
to demonstrate consistent effectiveness as an HIV prevention intervention in randomized
controlled trials (WHO and UNAIDS, 2007): three randomized controlled trials (RCTs) in
Kenya, Uganda, and South Africa reported a protective effect up to 60% of circumcision
against HIV infection. Subsequent studies have confirmed the value and persistence of MC's
protection against HIV infection and have demonstrated that MC also reduces the acquisition
and transmission of human papillomavirus.
A wide variety of instruments, devices, and techniques are used around the world for male
circumcision. In 2008, WHO, UNAIDS and JHPIEGO released a draft document entitled Manual for
Male Circumcision under Local Anesthesia, which includes step-by-step instructions for
performing adult male circumcision using three different surgical procedures: the
forceps-guided, dorsal slit, and sleeve resection methods. Procedure times for these
techniques are approximately 20-30 minutes excluding anesthesia, involve control of bleeding
and considerable suturing, and can be associated with a variety of complications.
Demand for MC, even in non-circumcising communities, is substantial when offered at no cost
in a safe setting (WHO and UNAIDS, 2007). In most African settings, only surgical
circumcision is available for most adults.
This is a prospective observational study of the PrePex device, which will be conducted with
the aim of ascertaining moderate and severe adverse events. This study will be conducted
within the context of routine service delivery in Lusaka, Zambia to identify potential
issues that must be addressed as MC services are scaled up. PrePex circumcision procedures
will be offered as part of the minimum package of HIV prevention services recommended by the
Zambian Ministry of Health (MOH), including HIV testing and counseling, provision of
Sexually Transmitted infection (STI) syndromic treatment, provision and promotion of
condoms, and counseling on risk-reduction and safer sex. This study will be conducted in
collaboration with the Zambia MOH and will follow recommendations for introductory study of
devices as laid out in the WHO's Framework for Evaluation of Circumcision Devices.
This study is a prospective study of adult male circumcision procedures conducted with the
PrePex MC device at two sites in Lusaka, Zambia. The investigators will enroll a total of
500 men aged 18 to 49 who are seeking voluntary medical male circumcision. The first 50 men
will undergo intensive follow-up with six scheduled visits, while the remaining 450 men will
be scheduled for two follow-up visits at 7 and 42 days after PrePex placement.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |